Antimicrobial peptides (AMPs) are nowadays understood as broad multifunctional tools of the innate immune system to fight microbial infections. In addition to its direct antimicrobial action, AMPs can modulate the host immune response by promoting or restraining the recruitment of cells and chemicals to the infection focus. Binding of AMPs to lipopolysaccharide is a critical step for both their antimicrobial action and their immunomodulatory properties. On the one hand, removal of Gram-negative bacteria by AMPs can be an effective strategy to prevent a worsened inflammatory response that may lead to septic shock. On the other hand, by neutralizing circulating endotoxins, AMPs can successfully reduce nitric oxide and tumor necrosis factor-α production, hence preventing severe tissue damage. Furthermore, AMPs can also interfere with the Toll-like receptor 4 recognition system, suppressing cytokine production and contributing to modulate the inflammatory response. Here, we review the immune system strategies devised by AMPs to avoid an exacerbated inflammatory response and thus prevent a fatal end to the host.

Keywords:
Peptide design, Peptide structure-activity relationship, Antibacterial peptides, Antimicrobial peptides, Endotoxin, Host defense, Immune response, Pathogen-associated molecular patterns, Pattern recognition receptors, Sepsis
1.
Murphy K: Janeway’s Immunobiology, ed 8. New York, Garland Science, 2011.
2.
Janeway CA Jr, Medzhitov R: Introduction: the role of innate immunity in the adaptive immune response. Semin Immunol 1998;10:349–350.
3.
Cohen J: The immunopathogenesis of sepsis. Nature 2002;420:885–891.
4.
Zhang X, Mosser DM: Macrophage activation by endogenous danger signals. J Pathol 2008;214:161–178.
5.
Israelachvili JN: Intermolecular and Surface Forces, ed 3. London, Academic Press, 2010.
6.
Seydel U, Wiese A, Schromm AB, Brandenburg K: A biophysical view in the function and activity of endotoxins; in Brade H, Opal S, Vogel S, Morrison D (eds): Endotoxin in Health and Disease. New York, Academic Press, 1999, pp 195–220.
7.
Mueller M, Lindner B, Dedrick R, Schromm AB, Seydel U: Endotoxin: physical requirements for cell activation. J Endotoxin Res 2005;11:299–303.
8.
Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, Schein RM, Sibbald WJ: Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest 1992;101:1644–1655.
9.
Wimley WC: Describing the mechanism of antimicrobial peptide action with the interfacial activity model. ACS Chem Biol 2010;5:905–917.
10.
Jenssen H, Hamill P, Hancock RE: Peptide antimicrobial agents. Clin Microbiol Rev 2006;19:491–511.
11.
Hancock RE, Diamond G: The role of cationic antimicrobial peptides in innate host defences. Trends Microbiol 2000;8:402–410.
12.
Zaiou M: Multifunctional antimicrobial peptides: therapeutic targets in several human diseases. J Mol Med (Berl) 2007;85:317–329.
13.
Bhunia A, Mohanram H, Bhattacharjya S: Lipopolysaccharide bound structures of the active fragments of fowlicidin-1, a cathelicidin family of antimicrobial and antiendotoxic peptide from chicken, determined by transferred nuclear Overhauser effect spectroscopy. Biopolymers 2009;92:9–22.
14.
Tack BF, Sawai MV, Kearney WR, Robertson AD, Sherman MA, Wang W, Hong T, Boo LM, Wu H, Waring AJ, Lehrer RI: SMAP-29 has two LPS-binding sites and a central hinge. Eur J Biochem 2002;269:1181–1189.
15.
Bhunia A, Domadia PN, Torres J, Hallock KJ, Ramamoorthy A, Bhattacharjya S: NMR structure of pardaxin, a pore-forming antimicrobial peptide, in lipopolysaccharide micelles: mechanism of outer membrane permeabilization. J Biol Chem 2010;285:3883–3895.
16.
Bhunia A, Saravanan R, Mohanram H, Mangoni ML, Bhattacharjya S: NMR structures and interactions of temporin-1Tl and temporin-1Tb with lipopolysaccharide micelles: mechanistic insights into outer membrane permeabilization and synergistic activity. J Biol Chem 2011;286:24394–24406.
17.
Bhunia A, Ramamoorthy A, Bhattacharjya S: Helical hairpin structure of a potent antimicrobial peptide MSI-594 in lipopolysaccharide micelles by NMR spectroscopy. Chemistry 2009;15:2036–2040.
18.
Almeida PF, Pokorny A: Mechanisms of antimicrobial, cytolytic, and cell-penetrating peptides: from kinetics to thermodynamics. Biochemistry 2009;48:8083–8093.
19.
McKeown AN, Naro JL, Huskins LJ, Almeida PF: A thermodynamic approach to the mechanism of cell-penetrating peptides in model membranes. Biochemistry 2011;50:654–662.
20.
Majerle A, Pristovsek P, Mancek-Keber M, Jerala R: Interaction of the HIV-1 gp120 viral protein V3 loop with bacterial lipopolysaccharide: a pattern recognition inhibition. J Biol Chem 2011;286:26228–26237.
21.
Su Y, Waring AJ, Ruchala P, Hong M: Structures of beta-hairpin antimicrobial protegrin peptides in lipopolysaccharide membranes: mechanism of Gram selectivity obtained from solid-state nuclear magnetic resonance. Biochemistry 2011;50:2072–2083.
22.
Zhang L, Dhillon P, Yan H, Farmer S, Hancock RE: Interactions of bacterial cationic peptide antibiotics with outer and cytoplasmic membranes of Pseudomonas aeruginosa. Antimicrob Agents Chemother 2000;44:3317–3321.
23.
Moore RA, Hancock RE: Involvement of outer membrane of Pseudomonas cepacia in aminoglycoside and polymyxin resistance. Antimicrob Agents Chemother 1986;30:923–926.
24.
Rosenfeld Y, Sahl HG, Shai Y: Parameters involved in antimicrobial and endotoxin detoxification activities of antimicrobial peptides. Biochemistry 2008;47:6468–6478.
25.
Rosenfeld Y, Lev N, Shai Y: Effect of the hydrophobicity to net positive charge ratio on antibacterial and anti-endotoxin activities of structurally similar antimicrobial peptides. Biochemistry 2010;49:853–861.
26.
Chapple DS, Hussain R, Joannou CL, Hancock RE, Odell E, Evans RW, Siligardi G: Structure and association of human lactoferrin peptides with Escherichia coli lipopolysaccharide. Antimicrob Agents Chemother 2004;48:2190–2198.
27.
Gough M, Hancock RE, Kelly NM: Antiendotoxin activity of cationic peptide antimicrobial agents. Infect Immun 1996;64:4922–4927.
28.
Scott MG, Vreugdenhil AC, Buurman WA, Hancock RE, Gold MR: Cutting edge: cationic antimicrobial peptides block the binding of lipopolysaccharide (LPS) to LPS binding protein. J Immunol 2000;164:549–553.
29.
Bhunia A, Mohanram H, Domadia PN, Torres J, Bhattacharjya S: Designed beta-boomerang antiendotoxic and antimicrobial peptides: structures and activities in lipopolysaccharide. J Biol Chem 2009;284:21991–22004.
30.
Domadia PN, Bhunia A, Ramamoorthy A, Bhattacharjya S: Structure, interactions, and antibacterial activities of MSI-594 derived mutant peptide MSI-594F5A in lipopolysaccharide micelles: role of the helical hairpin conformation in outer-membrane permeabilization. J Am Chem Soc 2010;132: 18417–18428.
31.
Torrent M, Andreu D, Nogues VM, Boix E: Connecting peptide physicochemical and antimicrobial properties by a rational prediction model. PLoS One 2011;6:e16968.
32.
Torrent M, Valle J, Nogues MV, Boix E, Andreu D: The generation of antimicrobial peptide activity: a trade-off between charge and aggregation? Angew Chem Int Ed Engl 2011;50:10686–10689.
33.
Kaconis Y, Kowalski I, Howe J, Brauser A, Richter W, Razquin-Olazaran I, Inigo-Pestana M, Garidel P, Rossle M, Martinez de Tejada G, Gutsmann T, Brandenburg K: Biophysical mechanisms of endotoxin neutralization by cationic amphiphilic peptides. Biophys J 2011;100:2652–2661.
34.
Mares J, Kumaran S, Gobbo M, Zerbe O: Interactions of lipopolysaccharide and polymyxin studied by NMR spectroscopy. J Biol Chem 2009;284:11498–11506.
35.
Bhunia A, Bhattacharjya S: Mapping residue-specific contacts of polymyxin B with lipopolysaccharide by saturation transfer difference NMR: insights into outer-membrane disruption and endotoxin neutralization. Biopolymers 2011;96:273–287.
36.
Mangoni ML, Epand RF, Rosenfeld Y, Peleg A, Barra D, Epand RM, Shai Y: Lipopolysaccharide, a key molecule involved in the synergism between temporins in inhibiting bacterial growth and in endotoxin neutralization. J Biol Chem 2008;283:22907–22917.
37.
Howe J, Andra J, Conde R, Iriarte M, Garidel P, Koch MH, Gutsmann T, Moriyon I, Brandenburg K: Thermodynamic analysis of the lipopolysaccharide-dependent resistance of Gram-negative bacteria against polymyxin B. Biophys J 2007;92:2796–2805.
38.
Thomas CJ, Surolia N, Surolia A: Kinetic and thermodynamic analysis of the interactions of 23-residue peptides with endotoxin. J Biol Chem 2001;276:35701–35706.
39.
Corradin SB, Mauel J, Gallay P, Heumann D, Ulevitch RJ, Tobias PS: Enhancement of murine macrophage binding of and response to bacterial lipopolysaccharide (LPS) by LPS-binding protein. J Leukoc Biol 1992;52:363–368.
40.
Gutsmann T, Muller M, Carroll SF, MacKenzie RC, Wiese A, Seydel U: Dual role of lipopolysaccharide (LPS)-binding protein in neutralization of LPS and enhancement of LPS-induced activation of mononuclear cells. Infect Immun 2001;69:6942–6950.
41.
Thompson PA, Kitchens RL: Native high-density lipoprotein augments monocyte responses to lipopolysaccharide (LPS) by suppressing the inhibitory activity of LPS-binding protein. J Immunol 2006;177:4880–4887.
42.
Wu X, Qian G, Zhao Y, Xu D: LBP inhibitory peptide reduces endotoxin-induced macrophage activation and mortality. Inflamm Res 2005;54:451–457.
43.
Wright SD, Ramos RA, Tobias PS, Ulevitch RJ, Mathison JC: CD14, a receptor for complexes of lipopolysaccharide (LPS) and LPS binding protein. Science 1990;249:1431–1433.
44.
Kim JI, Lee CJ, Jin MS, Lee CH, Paik SG, Lee H, Lee JO: Crystal structure of CD14 and its implications for lipopolysaccharide signaling. J Biol Chem 2005;280:11347–11351.
45.
Tapping RI, Tobias PS: Cellular binding of soluble CD14 requires lipopolysaccharide (LPS) and LPS-binding protein. J Biol Chem 1997;272:23157–23164.
46.
Kitchens RL, Thompson PA, Viriyakosol S, O’Keefe GE, Munford RS: Plasma CD14 decreases monocyte responses to LPS by transferring cell-bound LPS to plasma lipoproteins. J Clin Invest 2001;108:485–493.
47.
Yang D, Biragyn A, Hoover DM, Lubkowski J, Oppenheim JJ: Multiple roles of antimicrobial defensins, cathelicidins, and eosinophil-derived neurotoxin in host defense. Annu Rev Immunol 2004;22:181–215.
48.
Bowdish DM, Davidson DJ, Lau YE, Lee K, Scott MG, Hancock RE: Impact of LL-37 on anti-infective immunity. J Leukoc Biol 2005;77:451–459.
49.
Koyama Y, Motobu M, Hikosaka K, Yamada M, Nakamura K, Saido-Sakanaka H, Asaoka A, Yamakawa M, Sekikawa K, Kitani H, Shimura K, Nakai Y, Hirota Y: Protective effects of antimicrobial peptides derived from the beetle Allomyrina dichotoma defensin on endotoxic shock in mice. Int Immunopharmacol 2006;6:234–240.
50.
Schultz H, Weiss JP: The bactericidal/permeability-increasing protein (BPI) in infection and inflammatory disease. Clin Chim Acta 2007;384:12–23.
51.
O’Neill L: The Toll/interleukin-1 receptor domain: a molecular switch for inflammation and host defence. Biochem Soc Trans 2000;28:557–563.
52.
Lu YC, Yeh WC, Ohashi PS: LPS/TLR4 signal transduction pathway. Cytokine 2008;42:145–151.
53.
Prohinar P, Re F, Widstrom R, Zhang D, Teghanemt A, Weiss JP, Gioannini TL: Specific high affinity interactions of monomeric endotoxin. Protein complexes with Toll-like receptor 4 ectodomain. J Biol Chem 2007;282:1010–1017.
54.
Gioannini TL, Teghanemt A, Zhang D, Coussens NP, Dockstader W, Ramaswamy S, Weiss JP: Isolation of an endotoxin-MD-2 complex that produces Toll-like receptor 4-dependent cell activation at picomolar concentrations. Proc Natl Acad Sci USA 2004;101:4186–4191.
55.
Di Nardo A, Braff MH, Taylor KR, Na C, Granstein RD, McInturff JE, Krutzik S, Modlin RL, Gallo RL: Cathelicidin antimicrobial peptides block dendritic cell TLR4 activation and allergic contact sensitization. J Immunol 2007;178:1829–1834.
56.
Romano Carratelli C, Mazzola N, Paolillo R, Sorrentino S, Rizzo A: Toll-like receptor-4 (TLR4) mediates human beta-defensin-2 (HBD-2) induction in response to chlamydia pneumoniae in mononuclear cells. FEMS Immunol Med Microbiol 2009;57:116–124.
57.
Mookherjee N, Brown KL, Bowdish DM, Doria S, Falsafi R, Hokamp K, Roche FM, Mu R, Doho GH, Pistolic J, Powers JP, Bryan J, Brinkman FS, Hancock RE: Modulation of the TLR-mediated inflammatory response by the endogenous human host defense peptide LL-37. J Immunol 2006;176:2455–2464.
58.
Torrent M, Nogues MV, Boix E: Eosinophil cationic protein (ECP) can bind heparin and other glycosaminoglycans through its RNase active site. J Mol Recognit 2011;24:90–100.
59.
Guo JX, Wood SJ, David SA, Lushington GH: Molecular modeling analysis of the interaction of novel bis-cationic ligands with the lipid A moiety of lipopolysaccharide. Bioorg Med Chem Lett 2006;16:714–717.
60.
Bahl N, Du R, Winarsih I, Ho B, Tucker-Kellogg L, Tidor B, Ding JL: Delineation of lipopolysaccharide (LPS)-binding sites on hemoglobin: from in silico predictions to biophysical characterization. J Biol Chem 2011;286:37793–37803.
61.
Wasiluk KR, Leslie DB, Vietzen PS, Mayo KH, Dunn DL: Structure/function studies of an endotoxin-neutralizing peptide derived from bactericidal/permeability-increasing protein. Surgery 2004;136:253–260.
62.
Bruschi M, Pirri G, Giuliani A, Nicoletto SF, Baster I, Scorciapino MA, Casu M, Rinaldi AC: Synthesis, characterization, antimicrobial activity and LPS-interaction properties of SB041, a novel dendrimeric peptide with antimicrobial properties. Peptides 2010;31:1459–1467.
63.
Epand RF, Mor A, Epand RM: Lipid complexes with cationic peptides and oaks; their role in antimicrobial action and in the delivery of antimicrobial agents. Cell Mol Life Sci 2011;68:2177–2188.
64.
Ferguson AD, Kodding J, Walker G, Bos C, Coulton JW, Diederichs K, Braun V, Welte W: Active transport of an antibiotic rifamycin derivative by the outer-membrane protein FhuA. Structure 2001;9:707–716.
© 2012 S. Karger AG, Basel
2012
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.